Fig. 3

Interference with EGR1 expression affects the proliferative capacity of pancreatic cancer cells and can modulate cell sensitivity to Gemcitabine. (A–F) qRT-PCR and Western blot analysis showing the silencing efficiency of EGR1 in CFPAC-1 and PANC-1 cell lines. (G-H) Silenced or overexpressed CFPAC-1, and silenced or overexpressed PANC-1 cells were treated with different concentrations (0.01, 0.1, and 1 µmol/L) of gemcitabine for 48 h, and the cell viability was detected using the CCK8 assay. (I-J)Silenced or overexpressed CFPAC-1, silenced or overexpressed PANC-1 cells were treated with gemcitabine (0.1 µmol/L) for 24, 48, and 72 h, and cell viability was detected using the CCK8 assay.(K-L)CCK8 assay to detect IC50 in CFPAC-1 and PANC-1 cells silencing or overexpressing EGR1. (M-O) Flow cytometry of apoptosis of the indicated cells exposed to gemcitabine (1 µmol/L) for 48 h. (P)Representative fluorescent micrographs and quantification of EdU staining of the indicated cells after gemcitabine treatment (1 µmol/L) for 48 h.Scale bars: 200 μm.*P < 0.05; **P < 0.01; ***P < 0.001. Samples were from the same experiment and gels/blots were processed in parallel. β-actin was used as a loading control.